Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-30
2009-11-10
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C536S018700
Reexamination Certificate
active
07615528
ABSTRACT:
Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a recently discovered metabolic pathway. According to the normal functioning of this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins). Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3-deoxyglucosone (3DG).
REFERENCES:
patent: 4371374 (1983-02-01), Cerami et al.
patent: 4748174 (1988-05-01), Veronesi
patent: 4761368 (1988-08-01), Cerami
patent: 4798583 (1989-01-01), Beck et al.
patent: 4837170 (1989-06-01), Ohe et al.
patent: 5028625 (1991-07-01), Motola et al.
patent: 5108930 (1992-04-01), Ulrich et al.
patent: 5114943 (1992-05-01), Ulrich et al.
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5130324 (1992-07-01), Ulrich et al.
patent: 5130337 (1992-07-01), Ulrich et al.
patent: 5192753 (1993-03-01), McGeer et al.
patent: 5221683 (1993-06-01), Ulrich et al.
patent: 5231031 (1993-07-01), Szwergold et al.
patent: 5243071 (1993-09-01), Ulrich et al.
patent: 5258381 (1993-11-01), Ulrich et al.
patent: 5262152 (1993-11-01), Ulrich et al.
patent: 5272165 (1993-12-01), Ulrich et al.
patent: 5318982 (1994-06-01), Ulrich et al.
patent: 5334617 (1994-08-01), Ulrich et al.
patent: 5358960 (1994-10-01), Ulrich et al.
patent: 5468777 (1995-11-01), France et al.
patent: 5476849 (1995-12-01), Ulrich et al.
patent: 5877217 (1999-03-01), Ulrich et al.
patent: 5891341 (1999-04-01), Li
patent: 5892000 (1999-04-01), Founds
patent: 5935927 (1999-08-01), Vitek
patent: 5955481 (1999-09-01), Ohara
patent: 6004958 (1999-12-01), Brown et al.
patent: 7071298 (2006-07-01), Brown et al.
patent: 7033667 (1995-02-01), None
patent: 97/09981 (1997-03-01), None
patent: 98/43649 (1998-10-01), None
patent: 99/25690 (1999-05-01), None
T.R. Brown et al. Biochem. Soc. Trans. (2003) 31(6), pp. 1433-1437.
J.E. Tooke, “Perspectives in Diabetes Microvascular Function in Human Diabetes A Physiological Perspective”, Diabetes, 4: 721-725 (1995).
V.M. Monnier et al., “Accelerated age-related browning of human collagen in diabetes millitus”, Proc. Natl. Acad. Sci. USA, 81: 583-587 (1984).
J.H. Lee et al., “Glycosylation of Lens Proteins in Senile Cataract and Diabetes Millitus”, Biochem. Biophys. Res. Comm., 123: 888-893 (1984).
R.L. Engerman et al., “Progression of Incipient Diabetic Retinopathy During Good Glycemic Control”, Diabetes, 36: 808-812 (1987).
C.R. Harrington et al., “A glycation connection”, Nature, 370: 247-248 (1994).
K.H. Knecht et al., “Detection of 3-Deoxyfructose and 3-Deoxyglucosone in Human Urine and Plasma: Evidence for Intermediate . . . ”, Archives of Biochem., 294:130-137 (1992).
S. Reddy et al., “NE-(Carboxymethyl)lysine is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins”, Biochem, 34: 10872-19878 (1995).
T. Ikeda et al., NE-(Carboxymethyl)lysine Proteni Adduce is a Major Immunological Epitope in Proteins Modified with Advanced Glycation . . . , Biochem., 35: 8075-8083 (1996).
R. G. Khalifah et al., “Kinetics of Nonenzymatic Glycation of Ribonuclease a Leading to Advanced Glycation End Products . . . ”, Biochemistry., 35: 4645-4654 (1996).
M. Brownlee et al., “Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic . . . ”, The New England Journal of Medicine, 318: 1315-1321 (1988).
M. Brownlee et al., “Glycation and Diabetic Complications”, Diabetes, 43: 836-841 (1994).
M. Brownlee et al., “Glycation Productions and the Pathogeniesis of Diabetic Complications”, Diabetes Care, 15: 1835-1843 (1992).
T. Niwa et al., “Elevated Serum Levels of 3-Deoxyglucosone, a Potent Protein-Cross-Linking Intermediate of the Maillard Reaction . . . ”, Nephron, 69: 438-443 (1995).
W. L. Dills, Jr., “Protein fructosylation: Fructose and the MaillardReaction”, Am. J. Clin. Nutr., 58: 779S-787S (1993).
H. Yamada et al., “Increase in 3-Deoxyglucosine Levels in Diabetic Rat Plasma”, J. Biol. Chem., 269: 20275-20280 (1994).
N. Igaki et al., “Effects of 3-Deoxyglucosone on the Maillard Reaction”, Clin. Chem., 36: 631-634 (1990).
M. Takahashi et al., “In Vivo Glycation of Aldehyde Reductase, a Jajor 3-Deoxyglucosone Reducing Enzyme: Identification of Glycation Sites”, Biochem., 34: 1433 (1995).
E. Fujii et al., “The Presence of 2-Keto-3-deoxygluconic Acid and Oxoaldehyde Dehydrogenase Activity in Human Erythrocytes”, Biochem. Biophys. Res. Comm., 210: 852-857(1995).
O. Barski et al., “Mechanism of Human Aldehyde Reductase: Characterization of the Active Site Pocket”, Biochem., 34: 11264-11275 (1995).
F. Kappler et al., “Phosphorylated Amadori Products in Mammalian Kidneys”, Abstract presented at the Maillard Symposium, Aug. 29 to Sep. 1, 1993.
B. Su et al., “Identification of Tagatoselysine-3-Phosphate in Hyperglycemic Kidneys”, Abstracts presented at the Amer, Society of Nephrology conference, Oct. 26-29, 1994.
F. Kappler et al., “Metabolism of Fructoselysine in the Kidney”, Abstract presented at the American Society of Nephrology Meeting, Nov. 3-6, 1996.
B. Su et al., “Metabolism of Fructoselysine in the Kidney”, Abstract presented at the International Society of Magnetic Resonance Meeting, Apr. 27-May 3, 1996.
B.S. Szwergold et al., Identification of a Novel Phosphononester from Mammalian Kidneys as a.. Abstract presented at the Int'l Soc of Magnetic Resonance, Aug. 14-20, 1993.
Fox Chase Cancer Center Scientific Report, pp. 190-195 (1990-1991).
Fox Chase Cancer Center Scientific Report, pp. 214-217 (1991-1992).
Fox Chase Cancer Center Scientific Report, pp. 203-205 (1992-1993).
Fox Chase Cancer Center Scientific Report, pp. 175-178 (1993-1994).
Fox Chase Cancer Center Scientific Report, pp. 183-186 (1995).
A. Peterson et al., “Fructose metabolism in the human erythrocyte”, Biochem., 284: 363-366 (1992).
S. Lal et al., Metabolism of Fructose-3-phosphate in the Diabetic Rat Lens, Archives of Biochem. Biophys., 318: 191-199 (1995).
B. Szwergold et al., “Identification of Fructose-3-phosphate in the Lens of Diabetic Rats”, Science, 247: 451-454 (1990).
S. Lal et al., “Production of Fructose and Fructose-3-phosphate in Maturing Rat Lenses”, Investigative Ophthalmology & Visual Science, 36: 969-973 (1995).
B. Szwergold et al., “31P-Nuclear Magnetic Resonance Evidence of an Activated Hexose-Monophosphate Shunt in Hyperglycemic Rat Lenses in Vivo”, Diabetes, 44: 810-815 (1995).
F. Kappler et al., “Identification of Galactitol 2-Phosphate and Galactitol 3-Phosphate in the Lens of Galactose-Fed Rats”, Metabolism, 44: 1527-1531 (1995).
Medline 97104279, abstract of Fouda, “Effect of Lipopolysaccharide on Mitogen-activated Protein Kinases”, Biochemical Journal, 308 (Pt 3). pp. 815-822 (Jun. 1995).
Database EMBASE on STN, No. 93202080, abstract of Bares, R., “Pancreatic cancer detected by position emission tomography with 18F-labelled . . . ”, Nucl. Med. Comm. (1993).
Database EMBASE on STN, No. 85042856, abstract of Uchida, K., Altered bile acid metabolism in nonobese, spontane ously diabetic . . . , Diabetes (1985).
Database Medline on STN, US Nat'l Library of Medicine (Bethesda, MD), No. 95277969, abst of Fournier, N., “Reactivity of lechithin-cholesterol . . . ”, Clinica Chimica Acta (1995).
Database Medline on STN, US Nat'l Library of Medicine, (Bethesda MD) No. 90271410, abst of Suzuki S, “Assay of glycated fibrinogen . . . ”, Rin
Brown Truman R.
Keppler Francis
Dann Dorfman Herrell and Skillman, P.C.
Fox Chase Cancer Center
Hagan Patrick J.
Kosar Andrew D
LandOfFree
Methods for alleviating deleterious effects of 3-deoxyglucosone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for alleviating deleterious effects of 3-deoxyglucosone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for alleviating deleterious effects of 3-deoxyglucosone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084472